NVCR News
Novocures Optune Pax Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure (Nasdaq: NVCR) announced today that Japans Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. The approval of Optune Pax...
Business Wire
Novocures Optune Pax Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure (Nasdaq: NVCR) announced today that Japans Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. The approval of Optune Pax...
Business Wire
Novocure to Report Third Quarter 2026 Financial Results
Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 29, to discuss the companys financial results for the three-month...
Business Wire
NeOnc Goes After Brain Cancer’s Holy Grail: Getting Drugs Where They’re Needed
As brain cancer research moves toward increasingly targeted and sophisticated treatment strategies, NeOnc Technologies Holdings (NASDAQ:NTHI) is emerging as a company focused on one of the field’s central challenges: how to deliver therapeutic agents more effectively to the brain and tumors while navigating the formidable barriers that have historically limited treatment options.
24-7 Market News
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Zacks
Novocure Announces Upcoming Investor Events
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will take part in a fireside chat at 10:15 a.m. ET, as well as one-on-one meetings with...
Business Wire
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
Zacks
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks